Bendell JC et al. CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). Gastrointestinal Cancers Symposium 2021;Abstract TPS449.
Brastianos PK et al. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer 2021;2(5):498-502. Abstract
Camidge DR et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial. J Thorac Oncol 2021;16(12):2091-108. Abstract
Cho BC et al. Phase 1/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors. WCLC 2020;Abstract 3255.
Cooper AJ et al. Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant non-small cell lung cancer (NSCLC). ASCO 2022;Abstract e21024.
Dagogo-Jack I et al. A phase II study of capmatinib in patients with MET-altered lung cancer previously treated with a MET inhibitor. J Thorac Oncol May 2021;16(5):850-9. Abstract
Denlinger CS et al. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs 2021;39(6):1604-12. Abstract
Drilon A et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020;383(9):813-24. Abstract
Drilon A et al. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol 2021;18(1):35-55. Abstract
Dziadziuszko R et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol 2021;39(11):1253-63. Abstract
Gainor JF et al. Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs). ASCO 2022;Abstract e21178.
Gainor JF et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021;22(7):959-69. Abstract
Horn L et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial. JAMA Oncol 2021;7(11):1617-25. Abstract
Kalchiem-Dekel O et al. Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. ASCO 2022;Abstract 9080.
Le X et al. Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clin Cancer Res 2022;28(6):1117-26. Abstract
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract
Lin JJ, Gainor JF. An early look at selective RET inhibitor resistance: New challenges and opportunities. Br J Cancer 2021;124(11):1757-8. Abstract
Lin JJ et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 2020;31(12):1725-33. Abstract
Pennell NA et al. A first-in-human phase 1 study of the next-generation RET inhibitor LOXO-260 in RET inhibitor refractory patients with RET-altered cancers (trial in progress). ASCO 2022;Abstract TPS8595.
Petranovic M et al. Liquid biopsy, diagnostic imaging, and future synergies. J Am Coll Radiol 2022;19(2 Pt B):336-43. Abstract
Popat S et al. Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L. ESMO 2021;Abstract 1195P.
Sabari JK et al. Activity of adagrasib (MRTX849) in brain metastases: Preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer. Clin Cancer Res 2022;[Online ahead of print]. Abstract
Skoulidis F et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021;384(25):2371-81. Abstract
Subbiah V et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 Trial. Clin Cancer Res 2021;27(15):4160-7. Abstract
Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022;40(6):611-25. Abstract
Tanaka N et al. Clinical acquired resistance to KRAS G12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov 2021;11(8):1913-22. Abstract
Thai AA et al. Lung cancer. Lancet 2021;398(10299):535-54. Abstract
Wolf J et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. ASCO 2021;Abstract 9020.
Wu MY et al. Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation. Cancers (Basel) 2021;13(14):3572. Abstract